Teva-Handok acquires approval of ‘CINQAIR,’ biologic for treatment of severe asthma patients

Published: 2017-09-08 16:28:00
Updated: 2017-09-08 10:15:26

Teva-Handok(CEO Sun-Dong Park) announced that ‘CINQAIR(generic name: reslizumab),’ a new monoclonal antibody injection for the treatment of asthma, acquired approval from the Ministry of Food and Drug Safety on the 4th. 

CINQAIR is a monoclonal antibody(IgG4 kappa) targeting interleukin-5, a cyt...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.